Iluvien 0.19 MG implants
Ended Awarded
- Contract number
- SPE2DR26FQWB9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,427
Award facts
- Contract value 100% obligated
- $13,427.34 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $13,427.34 to DMS Pharmaceutical Group Inc. on November 17, 2025, for the supply of ILUVIEN 0.19 mg implants, a pharmaceutical product used in ophthalmologic treatment. This firm fixed-price delivery order, which carries an ultimate completion date of December 9, 2025, was awarded without set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, serves as a critical supplier within the Department of Defense's pharmaceutical supply chain.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The parent IDC, awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, positioning the contractor as one of multiple regional prime vendors supporting the $30.3 billion PPV-G GEN V acquisition strategy. Through this vehicle, DMS Pharmaceutical Group is authorized to supply a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FQWB9?
SPE2DR26FQWB9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 17, 2025.
How much is contract SPE2DR26FQWB9 worth?
The government has obligated $13,427 on SPE2DR26FQWB9.
Is contract SPE2DR26FQWB9 an order under another contract?
Yes. SPE2DR26FQWB9 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWB9 competed?
The extent of competition for SPE2DR26FQWB9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award